NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
LA JOLLA, Calif., March 07, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2016 financial results after the close of U.S. financial markets on March 14, 2017. Kura Oncology’s management will host a webcast and conference call at 4:30 p.m. EDT/1:30 p.m. PDT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 84483740. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 84483740.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The pipeline includes KO-947, an ERK inhibitor, and KO-539, an inhibitor of the menin-MLL protein-protein interactions. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 [email protected]
